3种药物治疗急性脑梗死的费用-效果分析  

Cost-effectiveness analysis of three therapeutic schemes for acute cerebral infarction

作　　者：黄好武 罗玉鸿[1] 梁飞华 

机构地区：[1]广东珠海市人民医院,珠海519000 [2]广东珠海市第二人民医院,珠海519000

出　　处：《海峡药学》2010年第5期235-236,共2页Strait Pharmaceutical Journal

摘　　要：目的探讨不同的药物治疗方案对同一疾病的效果,以找出最佳用药方案。方法运用药物经济学成本-效果分析方法 ,对降纤酶、低分子肝素钠、巴曲酶治疗急性脑梗死方案进行回顾性分析。结果 3种治疗方案的成本-效果比依次为10.88,24.46,22.62;不良反应发生率依次为11.76%,10.71%,2.38%。结论采用低分子肝素钠治疗急性脑梗死为最佳治疗方案。OBJECTIVE To observe the effect of different medication on the same disease,in order to find out the best therapeutic scheme.METHODS Using the methodology of cost-effectiveness analysis in the Pharmacoeconomics theory to make a review analysis of three therapeutic schemes in the treatment of acute cerebral infarction： Defibrase,Low-molecularweight heparin and Batroxobin.RESULTS The cost-effectiveness ratios of the three therapeutic schemes accordingly were 10.88,24.46 and 22.62,along with respective ratios of patient intolerance at 11.76%,10.71% and 2.38%.CONCLUSION To use Low-molecular-weight heparin is the best therapeutic scheme in the treatment of acute cerebral infarction.

关 键 词：成本-效果分析 药物经济学 急性脑梗死 

分 类 号：F404.4[经济管理—产业经济]